Loading
VP
Vaccitech plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Scheeren Joseph, was filed 28 Jun 2023.
Vaccitech plc: what insiders have been doing
Vaccitech plc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 11 filings came from 9 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Vaccitech plc has been absent for the past year.
For context, the typical company on the same exchange (median of 3,169 companies) published 24 filings over the same period, against 11 filings here. Looking back to 2021, when coverage begins, insiders filed 14 purchases and 15 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -66.4 m USD.
In the same sector, recent insider purchases at UCB also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
58
Thresholds
n/a
Buy Volume
€10M
14 ops. · all time
Sell Volume
€458,079
15 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
Income statement
Net income-59.1M
Last declaration on 11 September 2026
Declarations58 total
8,797,770 shares@ US$0.111100.0% of flowOrdinary SharesSEC:0001856079-26-000002:0
3,000 sharesOrdinary SharesSEC:0001104659-26-106337:0
361,530 sharesOrdinary SharesSEC:0001104659-26-106338:1
1,700 sharesOrdinary SharesSEC:0001104659-26-106323:0
728,454 sharesOrdinary SharesSEC:0001104659-26-106336:0
514,923 sharesOrdinary SharesSEC:0001104659-26-106336:1
361,530 sharesOrdinary SharesSEC:0001104659-26-106338:0
10,506 sharesOrdinary SharesSEC:0001104659-26-106340:0
3,000 sharesOrdinary SharesSEC:0001104659-26-106341:0
23,000 sharesOrdinary SharesSEC:0001104659-26-106342:0
48,256 sharesOrdinary SharesSEC:0001104659-26-106343:0
10,000 shares@ US$2.4420.2% of flowOrdinary SharesSEC:0001104659-23-075562:0
Canonical exit: 24 Sept 2023 (T+90)
13,750 shares@ US$2.662710.7% of flowOrdinary SharesSEC:0001104659-23-067081:0
Canonical exit: 23 Aug 2023 (T+90)
15,000 shares@ US$2.4199100.0% of flowOrdinary SharesSEC:0001104659-23-038357:0
4,108,752 shares0American Depositary SharesSEC:0001567619-22-018101:0
4,108,752 shares0American Depositary SharesSEC:0001567619-22-018100:0
450 shares@ US$4.780.7% of flowOrdinary SharesSEC:0001104659-22-095142:1
14,176 shares@ US$5.6926.1% of flowOrdinary SharesSEC:0001104659-22-095142:3
25,000 shares@ US$7.0757.1% of flowOrdinary SharesSEC:0001104659-22-095142:4
39,176 shares0Ordinary SharesSEC:0001104659-22-095142:2
10,000 shares@ US$7.38766.8% of flowOrdinary SharesSEC:0001104659-22-095144:0
450 shares@ US$0.00040.0% of flowOrdinary SharesSEC:0001104659-22-095142:0
649 shares@ US$4.771.0% of flowOrdinary SharesSEC:0001104659-22-092960:1
2,175 shares@ US$4.843.4% of flowOrdinary SharesSEC:0001104659-22-092960:3
2,175 shares0Ordinary SharesSEC:0001104659-22-092960:2
25 of 58 declarations
About Vaccitech plc
Vaccitech plc is a biotechnology company that emerged as a spin-out from the Jenner Institute at the University of Oxford, founded in May 2016. Its scientific founders include Professors Adrian Hill and Sarah Gilbert, both widely associated with infectious-disease vaccinology and viral-vector research. Vaccitech is known for co-inventing a COVID-19 vaccine with the University of Oxford, which was later licensed worldwide to AstraZeneca through Oxford University Innovation. For investors, the company should be viewed as a small-cap clinical biotechnology name that was listed in the United States on the NASDAQ under the ticker VACC, and operated as an international group with cross-border subsidiaries and U.S. reporting obligations.
At its core, Vaccitech’s business model has been research-driven rather than commercial. The company focused on the discovery and development of novel immunotherapeutics and vaccines designed to harness T-cell responses against chronic infectious diseases, cancer, and certain autoimmune conditions. Its technology base has been built around viral-vector platforms, which are intended to generate durable immune responses. In practical terms, that means Vaccitech has historically competed as a pipeline company: value creation depended on preclinical and clinical progress, regulatory milestones, and the ability to attract non-dilutive capital or partnership funding. Like many early-stage biotech developers, it did not have a broad, marketed product franchise; instead, it relied on the scientific and clinical potential of its programs.
Read moreShow less
Among its better-known development efforts were programs in chronic hepatitis B and other infectious-disease indications. The company’s positioning in the market has been shaped by this platform-centric approach and by the credibility derived from its Oxford origins. That said, the competitive landscape is intense. Vaccitech has faced competition from large vaccine manufacturers, specialty biotech developers, and other platform companies pursuing similar immunology and infectious-disease opportunities. Its moat has been less about commercial scale and more about scientific know-how, differentiated vectors, and the quality of clinical data generated over time.
A major corporate milestone came in 2023, when Vaccitech changed its name to Barinthus Biotherapeutics to better reflect a strategic shift toward T-cell immunotherapy in chronic infectious disease, autoimmunity, and cancer. This is important for investors reviewing historical filings: legacy documents may still refer to Vaccitech plc or its earlier corporate structure, while newer disclosures reflect the Barinthus identity. In other words, the company’s scientific continuity is more important than the branding change.
Geographically, Vaccitech was structured as a multinational biotech with subsidiaries in the United Kingdom, the United States, Australia, Italy, and Switzerland. For a French-speaking investor base, the key point is that this was a U.S.-reported NASDAQ-listed name in the United States, even though its scientific and corporate roots were in the UK. The most notable recent developments have centered on the company’s rebranding and continued emphasis on immune-mediated disease programs, reinforcing its profile as a specialized clinical-stage biotech rather than a diversified healthcare platform.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
